ReviewMolecular imaging
Targeting HER2 in Nuclear Medicine for Imaging and Therapy.
Review in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 81 citations in OpenAlex.
- Detection of HER2 expression usingBreast cancer research : BCR · 2024Trial
- Recent Advances in Radiopharmaceuticals for Cancer Diagnosis and Therapy.Oncology research · 2026Review
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- Complete preclinical evaluation of the novel antibody mimetic Nanofitin-IRDye800CW for diverse non-invasive diagnostic applications in the management of HER-2 positive tumors.Scientific reports · 2025Article
- Preclinical research progress in HER2-targeted small-molecule probes for breast cancer.Radiologie (Heidelberg, Germany) · 2024Review
- Development ofMolecular imaging and biology · 2024Article
- Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.Biomedicines · 2024Review
- Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis.Chemical science · 2024Review
- Development of antibody-drug conjugates in cancer: Overview and prospects.Cancer communications (London, England) · 2024Review
- Article
- PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.Journal of clinical medicine · 2023Review
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
- [Cancers · 2023Article
- Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracerJournal of translational medicine · 2023Article
- Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [American journal of nuclear medicine and molecular imaging · 2023Article
- Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine.Frontiers in molecular biosciences · 2023Review
- Clathrin light chain-conjugated drug delivery for cancer.Bioengineering & translational medicine · 2023Article
- Evaluation ofDiagnostics (Basel, Switzerland) · 2022Article
- Synthesis, Anticancer Activity and Molecular Docking Studies of NovelInternational journal of molecular sciences · 2022Article
- Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.Bioconjugate chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in the treatment of patients with HER2-positive cancer, they both require invasive biopsies for analysis. Moreover, the expression of HER2 is heterogeneous in breast cancer and can change over the course of the disease. Thus, the degree of HER2 expression in the small sample size of biopsied tumors at the time of analysis may not represent the overall status of HER2 expression in the whole tumor and in between tumor foci in the metastatic setting as the disease progresses. Unlike biopsy, molecular imaging using probes against HER2 allows for a noninvasive, whole-body assessment of HER2 status in real time. This technique could potentially select patients who may benefit from HER2-directed therapy and offer alternative treatments to those who may not benefit. Several antibodies and small molecules against HER2 have been labeled with different radioisotopes for nuclear imaging and/or therapy. This review presents the most recent advances in HER2 targeting in nuclear medicine focusing on preclinical and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.